Interaksi Warfarin dan Aspirin terhadap Risiko Perdarahan pada Pasien Penderita Penyakit Kardiovaskular
Bilah Samping Artikel
Isi Artikel Utama
Page: 728-739
Abstrak
Latar Belakang: Penyakit kardiovaskular (PKV) masih menjadi penyebab utama morbiditas dan mortalitas global, sehingga terapi antitrombotik seperti warfarin dan aspirin berperan penting dalam pencegahan kejadian tromboemboli. Kombinasi kedua obat ini memberikan efek sinergis dalam menghambat pembentukan trombus, namun meningkatkan risiko perdarahan secara signifikan. Tujuan: Mengevaluasi dampak penggunaan warfarin dan aspirin secara bersamaan terhadap risiko perdarahan serta manfaat klinisnya bagi pasien dengan PKV. Metode: Literatur sistematis dari Google Scholar dan Pubmed yang memenuhi kriteria inklusi dan dianalisis. Hasil: Penggunaan warfarin bersama aspirin meningkatkan kejadian perdarahan mayor tanpa memberikan manfaat tambahan dalam pencegahan stroke atau infark miokard. Selain itu, kontrol antikoagulasi yang buruk memperburuk risiko tersebut. Kesimpulan: Kombinasi warfarin dan aspirin sebaiknya hanya digunakan pada pasien dengan indikasi klinis yang kuat, sedangkan monoterapi warfarin lebih aman untuk pasien dengan kondisi stabil. Temuan ini menegaskan pentingnya evaluasi terapi individual dan pemantauan INR yang optimal guna menyeimbangkan manfaat dan risiko.
Unduhan
Rincian Artikel
Artikel ini berlisensiCreative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Referensi
World Health Organization, “Cardiovascular diseases (CVDs),” World Health Organization.
G. A. Mensah, V. Fuster, C. J. L. Murray, G. A. Roth, and lobal Burden of Cardiovascular Diseases and Risks Collaborators, “Global Burden of Cardiovascular Diseases and Risks, 1990-2022,” J. Am. Coll. Cardiol., vol. 82, no. 25, pp. 2350–2473, 2023, doi: 10.1016/j.jacc.2023.11.007.Global.
D. J. Kumbhani et al., “2020 ACC Expert Consensus Decision Pathway for Anticoagulant and Antiplatelet Therapy in Patients With Atrial Fibrillation or Venous Thromboembolism Undergoing Percutaneous Coronary Intervention or With Atherosclerotic Cardiovascular Disease,” J. Am. Coll. Cardiol., vol. 77, no. 5, pp. 629–658, 2021, doi: 10.1016/j.jacc.2020.09.011.
K. Sridharan and G. Sivaramakrishnan, “Hemorrhage risk associated with triple antithrombotic therapy : a focused real-world pharmacovigilance disproportional analysis study,” BMC Cardiovasc. Disord., vol. 25, no. 180, pp. 1–11, 2025, doi: https://doi.org/10.1186/s12872-025-04510-4.
K. C. Koskinas et al., “Duration of Triple Antithrombotic Therapy and Outcomes Among Patients Undergoing Percutaneous Coronary Intervention,” JACC Cardiovasc. Interv., vol. 9, no. 14, pp. 1473–1483, 2016, doi: 10.1016/j.jcin.2016.04.027.
ESC, “Worse outcomes with aspirin in high-risk chronic coronary syndrome patients who require long-term anticoagulation,” European Society of Cardiology. [Online]. Available: https://www.escardio.org/The-ESC/Press-Office/Press-releases/Worse-outcomes-with-aspirin-in-high-risk-chronic-coronary-syndrome-patients-who-require-long-term-anticoagulation
Z. Nurhafidah, I. L. Hilmi, and H. Sudarjat, “Analysis of the Side Effects of Long-Term Proton Pump Inhibitor (PPI) Use in Patients with Gastroesophageal Reflux Disease (GERD),” Heal. Tadulako J. (Jurnal Kesehat. Tadulako), vol. 11, no. 2, pp. 324–335, 2025.
M. Afriliana and E. Yuniarti, “Analisis Bibliometrik Respon Imun Pada Penyakit Leukemia Melalui Aplikasi Vosviewer,” J. Pendidik. Tambusai, vol. 8, no. 02, pp. 17248–177256, 2024.
R. Shah et al., “Use of concomitant aspirin in patients with atrial fibrillation: Findings from the ROCKET AF trial,” Am. Heart J., vol. 179, pp. 77–86, 2016, doi: 10.1016/j.ahj.2016.05.019.
M. Proietti and G. Y. H. Lip, “Impact of quality of anticoagulation control on outcomes in patients with atrial fi brillation taking aspirin : An analysis from the SPORTIF trials ☆,” Int. J. Cardiol., vol. 252, pp. 96–100, 2018, doi: 10.1016/j.ijcard.2017.10.091.
J. K. Schaefer et al., “Association of Adding Aspirin to Warfarin Therapy Without an Apparent Indication With Bleeding and Other Adverse Events,” JAMA Intern. Med., vol. 179, no. 4, pp. 533–541, 2019, doi: 10.1001/jamainternmed.2018.7816.
K. E. Kim, P. Yang, E. Jang, S. Kim, and B. Joung, “Antithrombotic Medication and the Risk of Vitreous Hemorrhage in Atrial Fibrillation : Korean National Health Insurance Service National Cohort,” Yonsei Med. J., vol. 60, no. 1, pp. 65–72, 2019.
C. J.-Y. Lee et al., “Antithrombotic Therapy and First Myocardial Infarction in Patients With Atrial Fibrillation,” J. Am. Coll. Cardiol., vol. 69, no. 24, pp. 2901–2909, 2017, doi: 10.1016/j.jacc.2017.04.033.
B. Turan, H. Demir, A. Mutlu, T. Daşlı, A. Erkol, and İ. Erden, “Inappropriate combination of warfarin and aspirin,” Anatol J Cardiol, vol. 16, pp. 189–196, 2016, doi: 10.5152/akd.2015.6050.
Z. M. Dimitrijevic, B. P. Mitic, D. D. Tasic, T. Vrecic, K. Paunovic, and S. Salinger, “Bleeding and Thrombotic Events in Hemodialysis Patients with Atrial Fibrillation on Anticoagulation and Antiplatelet Therapy : A 24-Month Cohort Study,” Medicina (B. Aires)., vol. 60, no. 1760, pp. 1–11, 2024, doi: https://doi.org/10.3390/medicina60111760.
M. L. Boyce, A. Zayac, A. Davis, T. Badrick, Sh. Anoopkumar-Dukie, and N. Bernaitis, “Impact of Aspirin on Warfarin Control as Measured by Time in Therapeutic Range,” Basic Clin. Pharmacol. Toxicol., vol. 123, no. 4, pp. 504–508, 2018, doi: 10.1111/bcpt.13037.
O. A. J. Altisent et al., “Warfarin and Antiplatelet Therapy Versus Warfarin Alone for Treating Patients With Atrial Fibrillation Undergoing Transcatheter Aortic Valve Replacement,” JACC Cardiovasc. Interv., vol. 9, no. 16, pp. 1706–1717, 2016, doi: 10.1016/j.jcin.2016.06.025.
S. Gulati et al., “Risk of intracranial hemorrhage (RICH) in users of oral antithrombotic drugs : Nationwide pharmacoepidemiological study,” PLoS, vol. 13, no. 8, pp. 1–15, 2018, doi: https://doi.org/10.1371/journal.pone.0202575 August.
G. Hindricks et al., "2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)," European Heart Journal, vol. 42, no. 5, pp. 373–498, Feb. 2021, doi: 10.1093/eurheartj/ehaa612.
A. S. Dewi, Z. Zulkarnain, dan E. N. Sholikhah, "Evaluation of Warfarin Use in Patients with Atrial Fibrillation at a Tertiary Hospital in Indonesia," Indonesian Journal of Pharmacy, vol. 32, no. 4, pp. 508-516, Des. 2021, doi: 10.22146/ijp.1562.
Xu H, Ruff CT, Giugliano RP, Murphy SA, Nordio F, Patel I, et al. Concomitant use of single antiplatelet therapy with edoxaban or warfarin in patients with atrial fibrillation: analysis from the ENGAGE AF-TIMI 48 trial. J Am Heart Assoc. 2016 Feb 23;5(2):e002587. doi:10.1161/JAHA.115.002587.
Watanabe E, Yamamoto M, Kodama I, Inoue H, Atarashi H, Okumura K, et al. Net clinical benefit of adding aspirin to warfarin in patients with atrial fibrillation: insights from the J-RHYTHM Registry. Int J Cardiol. 2016 Mar 19;212:311–7. doi:10.1016/j.ijcard.2016.03.008.